JP2020511440A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511440A5
JP2020511440A5 JP2019548380A JP2019548380A JP2020511440A5 JP 2020511440 A5 JP2020511440 A5 JP 2020511440A5 JP 2019548380 A JP2019548380 A JP 2019548380A JP 2019548380 A JP2019548380 A JP 2019548380A JP 2020511440 A5 JP2020511440 A5 JP 2020511440A5
Authority
JP
Japan
Prior art keywords
liquid pharmaceutical
pharmaceutical composition
adalimumab
glycerol
edta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019548380A
Other languages
English (en)
Japanese (ja)
Other versions
JP7357540B2 (ja
JP2020511440A (ja
Filing date
Publication date
Priority claimed from EP17159460.9A external-priority patent/EP3372242A1/en
Application filed filed Critical
Publication of JP2020511440A publication Critical patent/JP2020511440A/ja
Publication of JP2020511440A5 publication Critical patent/JP2020511440A5/ja
Priority to JP2023018934A priority Critical patent/JP2023058632A/ja
Application granted granted Critical
Publication of JP7357540B2 publication Critical patent/JP7357540B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019548380A 2017-03-06 2018-03-06 液体医薬組成物 Active JP7357540B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023018934A JP2023058632A (ja) 2017-03-06 2023-02-10 液体医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17159460.9 2017-03-06
EP17159460.9A EP3372242A1 (en) 2017-03-06 2017-03-06 Liquid pharmaceutical composition
PCT/EP2018/055505 WO2018162500A1 (en) 2017-03-06 2018-03-06 Liquid pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023018934A Division JP2023058632A (ja) 2017-03-06 2023-02-10 液体医薬組成物

Publications (3)

Publication Number Publication Date
JP2020511440A JP2020511440A (ja) 2020-04-16
JP2020511440A5 true JP2020511440A5 (cg-RX-API-DMAC7.html) 2021-04-08
JP7357540B2 JP7357540B2 (ja) 2023-10-06

Family

ID=58261543

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019548380A Active JP7357540B2 (ja) 2017-03-06 2018-03-06 液体医薬組成物
JP2023018934A Pending JP2023058632A (ja) 2017-03-06 2023-02-10 液体医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023018934A Pending JP2023058632A (ja) 2017-03-06 2023-02-10 液体医薬組成物

Country Status (4)

Country Link
US (2) US11534402B2 (cg-RX-API-DMAC7.html)
EP (2) EP3372242A1 (cg-RX-API-DMAC7.html)
JP (2) JP7357540B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018162500A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
PE20212185A1 (es) * 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN113727730A (zh) * 2019-03-18 2021-11-30 阿尔沃科技Hf公司 高浓度TNFα抗体的含水制剂

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
MEP90708A (hr) 2000-05-15 2011-12-20 Nova farmaceutska smješa
US20140186361A1 (en) * 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
CA2476934C (en) 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
CA2665567C (en) 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CA2690382A1 (en) 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
MX2011005672A (es) 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
KR101933197B1 (ko) 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
JP2015506369A (ja) 2012-01-30 2015-03-02 アレコー リミテッド 安定化された水性抗体組成物
KR20160105535A (ko) 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
WO2014114651A1 (en) 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US20170360929A1 (en) * 2014-12-23 2017-12-21 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
JP2018500380A (ja) 2014-12-31 2018-01-11 ノベルメド セラピューティクス,インコーポレーテッド アグリコシル化治療用抗体の製剤
EP3250598A1 (en) 2015-01-28 2017-12-06 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (en) 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
GB201703062D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
US20200069799A1 (en) 2018-08-28 2020-03-05 Arecor Limited Stabilized antibody protein solutions
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
WO2018184693A1 (en) 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2018184692A1 (en) 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2020511443A5 (cg-RX-API-DMAC7.html)
TWI478921B (zh) 醫藥調配物
TW201217343A (en) Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
JP2023029500A (ja) 抗ヒトtslp受容体抗体含有医薬組成物
EP2895164A1 (en) Pharmaceutical composition containing luliconazole
JP2013543505A5 (cg-RX-API-DMAC7.html)
JP6665350B2 (ja) 注射デバイスのための医薬ヒドロコルチゾン溶液
CN101909601B (zh) 使用甲氧基聚乙二醇增强难溶性活性剂的水溶解度的方法
JPH0741422A (ja) γ−オリザノールの水への可溶化方法
CN111374943A (zh) 药物组合物及其制备方法
JP6271696B2 (ja) 薬剤組成物、及びこれを密封してなる軟カプセル剤
CN1711095B (zh) 损伤皮肤修复用组合物
JPH0725735A (ja) 含嗽剤
JP5503939B2 (ja) アゼラスチン塩酸塩含有カプセル剤
JP4475405B2 (ja) 医薬組成物
JP4559111B2 (ja) 損傷皮膚修復用組成物
JP6925275B2 (ja) 皮膚用の医薬組成物
CN107072967B (zh) 用于递送药物和其他物质的口服组合物
JP4575705B2 (ja) 損傷皮膚修復用組成物
JP4575706B2 (ja) 損傷皮膚修復用組成物
CN104906591B (zh) 一种泰妙菌素胶体注射剂及其制备方法
JPWO2013154045A1 (ja) 注射剤用組成物
JP2019043853A (ja) 経皮吸収促進剤、経皮吸収促進助剤、及び経皮製剤
HK1169960B (en) Pharmaceutical formulation
JP2009013082A (ja) シラミ用シャンプーの製造方法